Clinical Trial

FMISO-based Adaptive Radiotherapy for Head and Neck Cancer

Study acronym: FARHEAD
Recruiting
View on ClinicalTrials.gov →
Record status
This record was last updated April 22, 2025 (before its estimated June 30, 2025 completion). Its status may not reflect the trial's current state.
Summary
Hypoxia occurs in about 80% of head and neck tumors. Based on experimental and clinical data, hypoxia is a useful parameter for pretherapeutic stratification. These radioresistant regions can be detected with FMISO PET/CT. Moreover, hypoxic subvolumes of tumors can be evolving as target volumes for radiotherapy ("dose painting") in hypoxia imaging-based dose escalation.
Protocol Amendment History 4 amendments
This ClinicalTrials.gov record has been amended 4 times since 2022-04-20; most recent amendment 2025-04-16.
Status change: Active, Not Recruiting → Recruiting 2024-01-04
Trial Details
NCT Number NCT05348486
Lead Sponsor University Hospital Olomouc
Collaborators: Masaryk Memorial Cancer Institute, University Hospital Ostrava
Conditions Head and Neck Cancer, Hypoxia, FMISO, Dose Escalation
Enrollment 120 participants
Start Date 2022-04-20
Primary Completion 2025-06-30 (estimated)
Study Completion 2030-06-30 (estimated)
Updated on ClinicalTrials.gov 2025-04-22